<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ALOSETRON</span><br/>(a-lo'se-tron)<br/><span class="topboxtradename">Lotronex<br/></span><b>Classifications:</b> <span class="classification">serotonin 5-ht<sub>3</sub> receptor antagonist</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Potent and selective serotonin (5-HT<sub>3</sub>) receptor antagonist. Serotonin 5-HT<sub>3</sub> receptors are extensively located on enteric neurons of the GI tract. Activation of these receptors affects amount of visceral
         pain experienced, transit time in the colon, and GI secretions.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Blockage of the serotonin 5-HT<sub>3</sub> receptors by alosetron results in significant control of GI pain, and severe diarrhea related to irritable bowel syndrome.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of severe irritable bowel syndrome (IBS) in women whose predominant symptom is diarrhea and whose symptoms have
         lasted &gt;6 mo and have failed to respond to conventional therapy.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Constipation, ischemic colitis, development of ischemic bowel symptoms such as sudden onset of rectal bleeding, bloody diarrhea,
         new or sudden worsening of abdominal pain; history of chronic or severe constipation, intestinal obstruction, toxic megacolon,
         GI adhesions, GI perforation, active diverticulitis, history of, or current Crohn's disease or ulcerative colitis; hypersensitivity
         to alosetron; thrombophlebitis, hypercoagulable state, inability to comply with PatientPhysician Agreement.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic insufficiency; pregnancy (category B), lactation; elderly. Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Irritable Bowel Syndrome</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 1 mg q.d. for 4 wk, may increase to 1 mg b.i.d. if tolerated<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure that the patient has signed the PatientPhysician Agreement prior to administering alosetron.</li>
<li>Do not give this drug if the patient has constipation.</li>
<li>Review the contraindications for this drug and ensure that the patient has none of the conditions for which the drug is contraindicated.</li>
<li>Store at 25° C (77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Malaise, fatigue, cramps, pain. <span class="typehead">CNS:</span>  Anxiety. <span class="typehead"> CV:</span> Tachyarrhythmias. <span class="typehead"> GI:</span>
<span class="speceff-both">Constipation</span>, abdominal pain, nausea, distention, reflux, hemorrhoids, hyposalivation, dyspepsia, <span class="speceff-life">ischemic colitis</span>. <span class="typehead">Skin:</span> Sweating, urticaria. <span class="typehead">Urogenital:</span> Urinary frequency. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Fluvoxamine</b> increases alosetron serum levels.					 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed, average bioavailability of 5060%. <span class="typehead"> Peak:</span> 1 h. <span class="typehead">Distribution:</span> 82% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized in liver. <span class="typehead">Elimination:</span> 73% excreted in urine, 24% excreted in feces. <span class="typehead">Half-Life:</span> 1.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report immediately signs of ischemic colitis such as new or worsening abdominal pain, bloody diarrhea, or
            blood in the stool.
         </li>
<li>Withhold drug and notify physician if patient has not had adequate control of IBS symptoms after 4 weeks of treatment with
            1 mg twice a day.
         </li>
<li>Monitor carefully patients who have decreased GI motility (e.g., older adults, persons receiving other drugs which may decrease
            GI motility) as they may be at greater risk of serious complications of constipation.
         </li>
<li>Monitor carefully patients with any degree of hepatic insufficiency as they may be more susceptible to adverse drug effects.</li>
<li>Monitor periodically for cardiac arrythmias, especially with preexisting cardiovascular disease.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Read the Medication Guide before starting alosetron and each time you refill your prescription.</li>
<li>Do not start taking alosetron if you are constipated.</li>
<li>Discontinue alosetron immediately and contact your physician if you experience any of the following: constipation, new or
            worsening abdominal pain, bloody diarrhea, or blood in the stool.
         </li>
<li>Contact your physician immediately if constipation does not resolve after discontinuation of alosetron. Resume alosetron again
            only if constipation has resolved and your physician directs you to begin taking the medication again.
         </li>
<li>Stop taking alosetron and contact your physician if IBS symptoms are not adequately controlled after 4 wk of taking 1 tablet
            twice a day.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>